Supplementary data for the manuscript: An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19

These figures provide: PF-07321332 plasma concentration vs. time data in Wistar Han rats and Cynomolgus monkeys following chronic oral administration of PF-07321332. Individual and mean animal (rats: n=30 (15 males & 15 females), monkeys: n=6 (3 males & 3 females)) plasma concentrations (vs. time) data are provided, which were also used to construct the curves depicted in Fig. 4A and Fig. 4B and estimate the corresponding toxicokinetics parameters.AndIndividual and median PF-07321332 plasma concentrations at nominal times in healthy participants after a single oral dose at PF-07321332 150 mg and PF-07321332 250 mg+RTV are included. The median concentration was used to generate figure 4C and 4D.